479413-68-8

479413-68-8 structure

Name: CUDA
Chemical Name: 12-(cyclohexylcarbamoylamino)dodecanoic acid
CAS Number: 479413-68-8
Molecular Formula: C₁₉H₃₆N₂O₃
Molecular Weight: 340.501
Catalog: Signaling Pathways Cell Cycle/DNA Damage PPAR
Create Date: 2017-12-31 11:35:22
Modify Date: 2025-08-23 16:57:41
CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively[1]. CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease[2].

Name	12-(cyclohexylcarbamoylamino)dodecanoic acid
Synonyms	cuda 12-[(Cyclohexylcarbamoyl)amino]dodecanoic acid Dodecanoic acid, 12-[[(cyclohexylamino)carbonyl]amino]-

Description	CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively[1]. CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease[2].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Cell Cycle/DNA Damage >> PPAR
Target	PPARα mouse sEH:11.1 nM (IC50) human sEH:112 nM (IC50)
In Vitro	CUDA (10 μM; 18 hours) produces 6- and 3-fold increases of PPARalpha in COS-7 cells[2]. CUDA does not alter PPARalpha protein expression, and it competitively inhibits the binding of Wy-14643 (pirinixic acid) to the ligand binding domain of PPARalpha, suggesting that it functions as a PPARalpha ligand[2]. Western Blot Analysis[2] Cell Line: COS-7 cells Concentration: 10 μM Incubation Time: 18 hours Result: Activated PPARα by binding to the ligand binding domain of PPARα.
References	[1]. Morisseau C, et al. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol. 2002 May 1;63(9):1599-608. [2]. Fang X, et al. Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther. 2005 Jul;314(1):260-70.